Orbem applies AI to MRI to uncover hidden insights
Orbem, a Munich-based DeepTech company, is working to transform Magnetic Resonance Imaging (MRI) from a traditional medical imaging modality into an AI-powered analytical tool capable of revealing previously inaccessible information in food and biological materials.
The company’s premise is straightforward: MRI generates rich, non-invasive signals, but translating those signals into actionable insights has often required specialized expertise, time-consuming interpretation, and use cases primarily centered on healthcare. Orbem is positioning its technology to expand MRI’s reach by pairing it with machine learning models designed to detect patterns and quantify characteristics that are difficult to observe through conventional inspection methods.
From imaging to measurement
MRI has long been valued for its ability to look inside objects without destroying them. In medicine, it helps clinicians visualize soft tissue. In industrial and scientific settings, it can be used to examine composition, structure, and internal changes over time. However, outside of clinical radiology, MRI’s broader adoption has been limited by cost, complexity, and the challenge of extracting consistent, repeatable measurements from scans.
Orbem aims to shift the emphasis from “pictures” to “measurements.” By applying artificial intelligence to MRI data, the company seeks to automate interpretation and identify subtle signals that may correlate with qualities such as internal defects, composition, or biological state. In practice, this approach could enable faster decisions in settings where internal inspection is valuable but destructive testing is undesirable.
Targeting food and biological applications
The company’s focus on food and biology highlights a growing interest in non-destructive testing across supply chains and research environments. In food production, stakeholders routinely need to assess quality, consistency, and safety—often at scale. Traditional methods can require sampling, cutting, chemical tests, or other procedures that are slow or waste product.
By contrast, MRI can examine internal structures without opening or altering the item being scanned. With AI layered on top, the resulting system could theoretically classify products, detect anomalies, or estimate internal attributes with less manual oversight. In biological contexts, the same combination of MRI and machine learning could help researchers analyze organisms or samples in ways that preserve them for further study.
While Orbem has not detailed specific commercial deployments in the provided information, the company’s positioning suggests an ambition to build a generalizable platform: MRI as a sensor, and AI as the translation layer that turns complex signals into usable outputs.
Why AI matters for MRI outside healthcare
MRI data is information-dense. The same scan can contain signals related to physical structure, water content, fat distribution, and other characteristics depending on how it is captured and processed. Interpreting that data reliably can be difficult, especially when moving beyond well-established clinical protocols.
AI can help in two ways. First, it can automate repetitive interpretation tasks, reducing reliance on scarce experts. Second, it can uncover correlations that are hard to detect with manual analysis, potentially enabling new kinds of measurements. For industrial and research users, this could translate into quicker throughput, more consistent results, and the ability to deploy MRI in settings where it has historically been impractical.
DeepTech momentum in Europe
Orbem fits into a broader European trend of DeepTech startups commercializing advanced sensing, imaging, and machine learning. Munich, in particular, has become a hub for engineering-heavy ventures spanning robotics, industrial software, and applied AI.
DeepTech companies typically face a different path than pure software startups: longer development cycles, more complex validation requirements, and the need to integrate hardware, data pipelines, and domain expertise. But when successful, they can establish defensible advantages through proprietary systems, specialized datasets, and high switching costs for customers.
What comes next
The key question for Orbem will be execution: proving that AI-enhanced MRI can deliver measurable value in real-world food and biology workflows. That includes demonstrating accuracy, repeatability, and speed, as well as integrating into operational environments where cost and throughput matter.
If the company can show that its approach reduces waste, improves quality control, or unlocks new research capabilities, it could help broaden MRI’s role beyond hospitals and imaging centers. The bigger vision is to make MRI not just a diagnostic tool, but a versatile, AI-powered instrument for understanding the internal properties of materials and living systems—without cutting them open.
Related
